代诺苏马布序列治疗的治疗策略:一个四臂随机对照试验
Hung-Kuan Yen1,2,3, Chia-Che Lee1,4, Chen-Yu Wang5,6
1Department of Orthopaedic Surgery, National Taiwan University Hospital, Taipei City, Taiwan.
Clinical pharmacology and therapeutics
|October 8, 2025
概括
在停止使用德诺苏马布后,有效的连续疗法至关重要. 两次佐列德罗纳特输液或恢复德诺苏马布显示有希望的骨矿物质密度的保存,与单次佐列德罗纳特输液之后的无药期不同.
科学领域:
- 骨质疏松症的管理
- 对骨健康的药理干预措施
背景情况:
- 停止服用登苏马布可以导致反弹骨损失和骨折风险增加.
- 确定有效的顺序疗法对于减轻这些风险至关重要.
- 代诺苏玛布序列治疗 (DST) 试验研究了代诺苏玛布后的治疗策略.
研究的目的:
- 为了评估不同连续疗法的有效性,在停止使用denosumab后.
- 为了比较连续的denosumab治疗与基于zoledronate的疗法.
- 评估骨矿物质密度的变化和骨折发生率.
主要方法:
- 这是一项为期两年的多中心随机对照试验 (DST试验),涉及101名50岁以上的患者.
- 四个手臂:持续使用denosumab,每年两次注射zoledronate,一次注射zoledronate之后一年不使用药物,或者一次注射zoledronate之后注射denosumab.
- 主要结局:腰椎,部和股骨部骨矿物质密度 (BMD) 的百分比变化.
主要成果:
- 腰椎骨质量在代诺苏玛布 (+1.77%) 和双切换 (+2.25%) 组中增加.
- 腰椎骨髓骨质量在每年使用佐勒多纳特 (-0.71%) 和两年使用佐勒多纳特 (-2.76%) 组下降.
- 三分之一的患者在两年一次的zoledronate组经历了显著的骨损失;22%需要救援zoledronate.
结论:
- 由于显著的骨质损失,不建议进行单次佐莱德罗纳特输液,然后再进行无药一年.
- 每年连续两次注射佐勒多酸盐可提供有前途的BMD保护.
- 在一次佐勒德罗纳特输液 (双切换) 后恢复德诺苏马布是维持BMD的可行的替代方案.
更多相关视频
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
1.0K
08:53Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
9.7K
相关概念视频
01:26Angina IV: Management
236
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
236
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
207
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
207